The phrase "a rationale for testing" is correct and usable in written English.
It can be used when discussing the reasoning or justification behind conducting tests in various contexts, such as education, research, or product development.
Example: "The report outlines a rationale for testing the new software to ensure its functionality and user satisfaction."
Alternatives: "a justification for testing" or "a reason for testing".
These results provide a rationale for testing the combination of Yondelis and DDP in the clinic.
The results of population studies, pre-clinical research and clinical studies in patients with metastatic disease provided a rationale for testing bone-targeted agents in the adjuvant setting.
Our results provide a rationale for testing a hypothesis that early therapeutic vaccination (e.g., within two months p/s) may prevent reverse mutations and reduce viral set point.
Our data thus provide a rationale for testing whether hydroxyurea and other HbF-inducing agents can be used as prophylaxis against severe and fatal malaria in very young 'wildtype' children who lack protective polymorphisms.
The presence of DTCs after chemotherapy clearly indicates a rationale for testing of alternative (secondary) treatment approaches.
The findings of our study provide a rationale for testing the therapeutic effects of pazopanib in patients with unresectable HCC.
Overall, these data demonstrate that vaccination with chemically attenuated parasites induces protective immunity and provide a compelling rationale for testing a blood-stage parasite-based vaccine targeting human Plasmodium species.
In general, the detailed characterisation of the biological properties of a particular pathophysiological factor could provide a logical rationale for testing its potential prognostic significance as a biomarker in HCC.
Similarly, the emerging importance of Braf as a target in melanoma provides a strong rationale for testing new Braf inhibitors with radiation in melanoma cell lines.
We present a general forward-looking policy framework and use it to provide a formal rationale for testing when policymakers can and cannot expect to be able to manage expectations.
Our findings provide, for the first time, a molecular rationale for testing JAK2 inhibitors, specifically Lestaurtinib, in HL patients.
